FDA won't accept Merck's application for new drug

November 2, 2009 By LINDA A. JOHNSON , AP Business Writer
FILE - In this May 22, 2008 file photo, the company logo is seen on the doors of a building at Merck & Co. headquarters in Whitehouse Station, N.J. U.S. regulators won't accept drugmaker Merck's application Monday, Nov. 2, 2009, for a new combination cholesterol pill that includes rival Pfizer's Lipitor, the world's top-selling drug. (AP Photo/Mel Evans, file)

(AP) -- U.S. regulators have refused to accept drugmaker Merck & Co.'s application for a new, combination cholesterol pill that includes rival Pfizer's Lipitor, the world's top-selling drug.

Merck disclosed the rare move by the Food and Drug Administration in a regulatory filing Monday.

The company 2 1/2 years ago said it planned to make a dual cholesterol pill that at the time looked sure to be a blockbuster: a combination of Pfizer Inc.'s Lipitor - which generates nearly $13 billion in annual sales - and Zetia, a cholesterol pill Merck sells with Schering-Plough Corp. The two drugmakers have been partners on cholesterol medicines since 2000 and are about to merge.

Merck, of Whitehouse Station, N.J., applied to the FDA in September for approval of the combo pill. But Merck said the FDA refused to file the application and instead is requiring more data on the manufacturing and stability of the drug.

"For a company this size, this is not the norm," said analyst Steve Brozak, president of WBB Securities.

Normally, when companies seek approval of an experimental drug, the FDA accepts the application and spends months reviewing it. Most contain thousands of pages of data on testing of the drug in people and animals, details about the manufacturing process and information about how long the drug remains stable and effective.

After a thorough review by FDA staff, if the data is deemed inadequate or otherwise problematic, they usually require further information and sometimes additional patient studies.

In this case, the FDA would not file the application.

Merck's filing with the Securities and Exchange Commission states the FDA "has identified additional manufacturing and stability data that are needed."

"We do intend to refile" with additional data, said Merck spokesman Ron Rogers.

Brozak said the agency, which has become increasingly cautious and unpredictable in its decisions, might only have minor questions on the details.

"Or, it could mean that they've found something they don't like," he said.

One possibility, he added, is that Merck and Schering-Plough took a common shortcut on stability testing by heating the combo pills to a high temperature, rather than monitoring them at room temperature for the standard two or three years of shelf life.

Because Pfizer holds patents on Lipitor, Merck and Schering-Plough would not be able to sell their combo pill - assuming it does get approved - until those patents expire. That happens as early as next year in some countries. In the U.S., generic competition is expected starting on Nov. 30, 2011.

FDA spokespeople could not immediately say how often applications are rejected upfront.

Merck is about to acquire Schering-Plough for $41.1 billion in a deal expected to close shortly. U.S. and other antitrust regulators have recently approved it.

The two New Jersey companies already sell a cholesterol combo pill, Vytorin. It contains Zetia, which limits the cholesterol absorbed from food, and Merck's older cholesterol drug Zocor, which reduces how much cholesterol the body produces due to family history.

Lipitor works the same way as Zocor, but research shows it's more effective at preventing heart attacks, strokes and death. That could make a Lipitor-Zetia pill very popular.

Still, any sales likely will be less than what Merck and Schering-Plough once envisioned, Brozak said, with health care reform imminent and cheap generic Zocor grabbing a growing share of the cholesterol market.

shares rose 33 cents, or 1.1 percent, to close at $31.26 Monday. Schering-Plough gained 20 cents to end at $28.40, while Pfizer shares shed 8 cents to $16.95.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Related Stories

Recommended for you

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

Non-psychotropic cannabinoids show promise for pain relief

September 4, 2017
Some cancers love bone. They thrive in its nutrient-rich environment while gnawing away at the very substrate that sustains them, all the while releasing inflammatory substances that cause pain—pain so severe that opioids ...

Fentanyl drives rise in opioid-linked deaths in U.S.

August 31, 2017
(HealthDay)—Fentanyl, a synthetic narcotic, is a key player in America's continuing epidemic of opioid-related overdose deaths, two new studies report.

Eating triggers endorphin release in the brain

August 28, 2017
Finnish researchers have revealed how eating stimulates brain's endogenous opioid system to signal pleasure and satiety.

Cholesterol-lowering drugs may fight infectious disease

August 21, 2017
That statin you've been taking to lower your risk of heart attack or stroke may one day pull double duty, providing protection against a whole host of infectious diseases, including typhoid fever, chlamydia, and malaria.

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.